| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Collaboration revenue | $0 | $0-100.0% | $7.0M | $0 | $0 |
| Research and development | $33.8M-48.7% | $65.7M-23.3% | $85.7M+68.0% | $51.0M+31.0% | $38.9M |
| General and administrative | $18.5M-20.9% | $23.4M-11.9% | $26.5M+31.7% | $20.2M+28.2% | $15.7M |
| Restructuring and impairment charges | $6.8M+365.1% | $1.5M-76.2% | $6.2M | $0 | $0 |
| Total operating expenses | $59.1M-34.8% | $90.6M-23.5% | $118.4M+66.4% | $71.2M+30.2% | $54.7M |
| Loss from operations | -$59.1M+34.8% | -$90.6M+18.7% | -$111.4M-56.6% | -$71.2M-30.2% | -$54.7M |
| Interest income | $4.4M-47.5% | $8.5M-23.8% | $11.1M+170.3% | $4.1M+2085.1% | $188K |
| Other expenses | -$1.4M+14.0% | -$1.6M-2.8% | -$1.6M | — | — |
| Net loss | -$56.0M+33.1% | -$83.7M+17.8% | -$101.9M-49.3% | -$68.2M-24.9% | -$54.6M |
| Net loss per common share, basic (in dollars per share) | -$7660.00+33.3% | -$11490.00+18.2% | -$14040.00-38.6% | -$10130.00-874.0% | -$1040.00 |
| Net loss per common share, diluted (in dollars per share) | -$7660.00+33.3% | -$11490.00+18.2% | -$14040.00-38.6% | -$10130.00-874.0% | -$1040.00 |
| Weighted-average shares used to compute net loss per common share, basic (in shares) | $7316890000.00+0.4% | $7290245000.00+0.5% | $7255365000.00+7.7% | $6736894000.00-87.2% | $52759335000.00 |
| Weighted-average shares used to compute net loss per common share, diluted (in shares) | $7316890000.00+0.4% | $7290245000.00+0.5% | $7255365000.00+7.7% | $6736894000.00-87.2% | $52759335000.00 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.